Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 7.37M P/E - EPS this Y 98.10% Ern Qtrly Grth -
Income -34.93M Forward P/E -0.48 EPS next Y 17.80% 50D Avg Chg -68.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -97.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -99.00%
Recommedations 2.00 Quick Ratio 0.17 Shares Outstanding 14.60M 52W Low Chg 23.00%
Insider Own 2.91% ROA -114.54% Shares Float 14.54M Beta 1.06
Inst Own 0.08% ROE -3,230.05% Shares Shorted/Prior 859.32K/150.71K Price 0.51
Gross Margin - Profit Margin - Avg. Volume 1,921,121 Target Price 5.75
Oper. Margin - Earnings Date May 10 Volume 440,194 Change -4.72%
About Panbela Therapeutics, Inc.

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Panbela Therapeutics, Inc. News
03/22/23 Panbela Announces Issuance of New Patent in Japan; Patent is for Claims of a Novel Process for the Production of SBP-101
03/18/23 When Will Panbela Therapeutics, Inc. (NASDAQ:PBLA) Become Profitable?
03/16/23 Panbela Provides Business Update and Reports Q4 and FY 2022 Financial Results
03/08/23 Panbela to Host Fourth Quarter and Year End 2022 Earnings Conference Call on March 16, 2023
03/07/23 Panbela Announces First Patient Enrolled in South Korea for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
03/01/23 Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)
02/13/23 Panbela Announces Closing of Approximately $15 Million Public Offering, and Regains Compliance with Nasdaq Listing Standards
01/26/23 Panbela Announces Pricing of Approximately $15 Million Public Offering
01/19/23 Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
01/12/23 Panbela Announces 1-for-40 Reverse Stock Split effective January 13, 2023
01/11/23 Panbela Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRF
12/14/22 Panbela Receives Positive EMA Opinion on Orphan Designation for Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
11/28/22 Panbela Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
11/10/22 Panbela Provides Business Update and Reports Q3 2022 Financial Results
10/31/22 Panbela Schedules Conference Call on, November 10, 2022, to Report 2022 Third Quarter Financial Results
10/06/22 Panbela to Participate in the Roth Inaugural Healthcare Opportunities Conference
09/30/22 Panbela Announces Pricing of Approximately $6 Million Public Offering
09/29/22 Panbela Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
08/15/22 Panbela Provides Business Update and Reports Q2 2022 Financial Results
08/11/22 Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
PBLA Chatroom

User Image Patienceplease Posted - 5 minutes ago

$PBLA … R.I.P .. took the loss here at 1.36 🙏🏻

User Image DaddyDeano27 Posted - 25 minutes ago

$PBLA At literally anytime this will triple or more, float etc

User Image RubbereRobby Posted - 27 minutes ago

$PBLA The only way to get this up is getting positive news on the stage of their developments. I invest in this purely because of their focus on cancer treatments. I lost many friends because of cancer and want to give this company a fair chance. Success Panbela

User Image DaddyDeano27 Posted - 39 minutes ago

$PBLA Waiting for Hunter or Monica to buy in then I'm all in.

User Image Suffix Posted - 1 hour ago

$PBLA did this actually touch .41 before?

User Image ReverseSplit25 Posted - 1 hour ago

$PBLA now we go to .60 🙏

User Image EVOTZ Posted - 1 hour ago

$PBLA op

User Image Espressolife4me Posted - 1 hour ago

$PBLA NO BOTTOM!!!TILL ZERO!!

User Image bj1983 Posted - 1 hour ago

$PBLA come on give us some decent news. You just can't make this up! Let's go!

User Image 1Cyber1 Posted - 1 hour ago

$PBLA Hello Mothafakas.. still holding this shit?

User Image biggmakk Posted - 2 hours ago

$PBLA shorts have 0 to worry about as you can see by short interest they can short daily and convert warrants to cover the short

User Image susu4 Posted - 2 hours ago

$PBLA shorts don‘t get shares anymore…they are desperately selling to themselves hoping to trigger sells from outside.

User Image ReverseSplit25 Posted - 2 hours ago

$PBLA need volume, as in like 5mill for any significant move

User Image Stockgasm Posted - 2 hours ago

$PBLA Bears get the lube out it's time for therapy

User Image DaddyDeano27 Posted - 2 hours ago

$PBLA I hope this goes to $5+ and all the shorts shart there pants 👖

User Image Max1millionn Posted - 2 hours ago

$PBLA lol

User Image Stockgasm Posted - 2 hours ago

$PBLA loading zone Bears I see you $0.55.60.80 $1.48 scaled in

User Image ineedmore Posted - 2 hours ago

$PBLA always with mid morning or mid day drops. Very manipulated. Maybe too much.

User Image Tradelyfe Posted - 2 hours ago

$PBLA still going down I see? Wild

User Image Market_Magician Posted - 2 hours ago

$PBLA buying more

User Image bj1983 Posted - 2 hours ago

$PBLA Doubled my position. 30k shares now. Now they may let her run!

User Image Mucho_Dinaro Posted - 2 hours ago

$PBLA What bleeding are you talking about ?

User Image ReverseSplit25 Posted - 2 hours ago

$PBLA I’ll tell ya what, from these levels it’s either gonna go up or go down

User Image STESSA Posted - 2 hours ago

$PBLA this looks exhausted 🥱… run is coming.

User Image moneygrabber55 Posted - 2 hours ago

$PBLA this sucks, when is the bleeding gonna stop

User Image Mucho_Dinaro Posted - 3 hours ago

$PBLA When you look at the trades going through, you notice there knocking down the price 50 -100 shares at a time.

User Image ineedmore Posted - 3 hours ago

$PBLA market gap is now 7m? How’s that possible

User Image Moonlightxx Posted - 3 hours ago

$PBLA New here. How did it go to $87 before? On what news?

User Image topstockalerts Posted - 5 hours ago

$PBLA it should break over $.60 today. Primed to pull a big move. $1.50 target on this swing

User Image TimingTimingTiming Posted - 6 hours ago

$PBLA A wise investor once posted here that patience is the key to trading success. I agree with that. Holding https://giphy.com/gifs/kim-novak-tXL4FHPSnVJ0A

Analyst Ratings
Maxim Group Buy Mar 20, 23
Maxim Group Hold Oct 12, 22
Roth Capital Buy Jun 28, 21
Maxim Group Buy Mar 10, 21